Absence of direct effects on the dopamine D2 receptor by mGluR2/3-selective receptor agonists LY 354,740 and LY 379,268

Synapse

Volumn 65, Issue 1, 2011, Pages 64-68

  Zysk, John R ^a   Widzowski, Dan ^a   Sygowski, Linda A ^a   Knappenberger, Katharine S ^a   Spear, Nathan ^a   Elmore, Charles S ^a   Dorff, Peter ^a   Liu, Hongyan ^a   Doherty, James ^a   Chhajlani, Vijay ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

D2 receptor; Glutamate agonist; LY 354,740; LY 379,268

Indexed keywords

4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; DOMPERIDONE; DOPAMINE 2 RECEPTOR; EGLUMETAD; MEGLUMINE; NAXAGOLIDE; RACLOPRIDE;

ANIMAL CELL; ARTICLE; BINDING ASSAY; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; IONIC STRENGTH; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL;

AMINO ACIDS; ANIMALS; BICYCLO COMPOUNDS; BICYCLO COMPOUNDS, HETEROCYCLIC; BINDING, COMPETITIVE; CHO CELLS; CRICETINAE; CRICETULUS; DOMPERIDONE; EXCITATORY AMINO ACID AGONISTS; MASS SPECTROMETRY; RACLOPRIDE; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE D2; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 77954106981     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20817     Document Type: Article

References (16)

1. Cartmell J, Monn JA, Schoepp DD. 1999. The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus D-amphetamine motor behaviors in rats. J Pharmacol Exp Ther 291: 161-170.
2. Fell MJ, Johnson BG, Falcone JF, Perry KW, Barth VN, Rash KS, Monn JA, Schoepp DD, McKinzie DL, Nelson DL, Marek GJ, Svensson KA. 2008. In vivo neurochemical and behavioral evidence for lack of direct dopamine D2 receptor mediated actions of mGluR2/3 agonists. Abstr Soc Neurosci Poster 155.7.
3. Fell MJ, Perry KW, Falcone JF, Johnson BG, Barth VN, Rash KS, Lucaites VL, Threkeld PG, Monn JA, McKinzie DL, Marek GJ, Svensson KA, Nelson DL. 2009. In vitro and in vivo evidence for a lack of interaction with dopamine D2 receptors by the mGlu2/3 receptor agonists LY354740 and LY379268. Synapse 331: 1126-1136.
4. Freeman ME, Kanyicska B'L, Lerant A, Nagy G. 2000. Prolactin: Structure, function and regulation of secretion. Physiol Rev 80: 1523-1631.
5. Johnson MP, Chamberlain M. 2002. Modulation of stress-induced and stimulated hyperprolactinemia with the group II metabotropic glutamate receptor selective agonist. LY379268. Neuropharmacology 43: 799-808.
6. 3H]raclopride are indistinguishably inhibited by D2 agonists and antagonists ex vivo. Nucl Med Biol 35: 11-17.
7. Musset F, Bertrand P, Priam M, Kordon C, Enjalbert A. 1991. Differential mechanisms of dopamine and somatostatin inhibition of prolactin secretion from anterior pituitary cells. J Neuroendocrinol 3: 21-28.
8. 3H-raclopride in vivo. Synapse. Epub ahead of print 22 March 2010, DOI 20771.
9. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, et al. 2007. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized Phase 2 clinical trial. Nat Med 13: 1102-1107.
10. i-coupled GPCRs. J Biomol Screen 12: 312-319.
11. Seeman P. 2008. Glutamate agonists for schizophrenia stimulate dopamine D2 high receptors. Schizophr Res 99: 373-374.
12. High and D3 receptors. Synapse 63: 705-709.
13. Seeman P, Ulpian C, Larsen RD, Anderson PS. 1993. Dopamine receptors labeled by PHNO. Synapse 14: 254-262.
14. Seeman P, Caruso C, Lasaga M. 2008. Dopamine partial agonist actions of the glutamate receptor agonists LY 354, 740 and LY 379, 268. Synapse 62: 154-158.
15. Woolley ML, Pemberton DJ, Bate S, Corti C, Jones DN. 2008. The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist. LY379268, in mouse models predictive of antipsychotic activity. Psychopharmacology (Berl) 196: 431-440.
16. Zysk J, Knappenberger KS, Sygowski LA, Spear N, Elmore C, Dorff P, Liu H. 2008. No direct effects observed on dopamine D2 receptor binding or function by the mGluR2/3-selective agonists LY354, 740 and LY 379, 268. Abstr Soc Neurosci Poster 155.4.